Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 
165 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Libtayo (cemiplimab-rwlc) / Regeneron
2021-006372-17: A study to investigate the clinical and immunological effects on field cancerization in patients treated with PD-1 inhibition for advanced or metastatic cutaneous squamous cell carcinoma

Not yet recruiting
4
20
Europe
Cemiplimab, Concentrate and solvent for solution for infusion, LIBTAYO®
Muehlenkreiskliniken AoeR, Sanofi-Aventis
advanced or metastatic cutaneous squamous cell carcinoma, Advanced squamous cell carcinoma of the skin, Diseases [C] - Cancer [C04]
 
 
EMPOWER-Cervical 1, NCT03257267 / 2017-000350-19: Study of Cemiplimab in Adults With Cervical Cancer

Checkmark Approved in Japan for the treatment of advanced or recurrent cervical cancer based on EMPOWER-Cervical 1 trial
Dec 2022 - Dec 2022: Approved in Japan for the treatment of advanced or recurrent cervical cancer based on EMPOWER-Cervical 1 trial
Checkmark Approved for adult patients with recurrent or metastatic cervical cancer based on EMPOWER-Cervical 1 trial
Nov 2022 - Nov 2022: Approved for adult patients with recurrent or metastatic cervical cancer based on EMPOWER-Cervical 1 trial
Checkmark Post-hoc exploratory analysis of P3 EMPOWER-Cervical 1 trial in advanced cervical cancer at ESMO-IO 2022
More
Completed
3
608
Europe, Canada, Japan, US, RoW
Cemiplimab, REGN2810, Libtayo, Investigator Choice (IC) Chemotherapy
Regeneron Pharmaceuticals, Sanofi
Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
03/21
04/23
EMPOWER-Lung 3, NCT03409614 / 2017-001311-36: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Dec 2019 - Dec 2023: Approval for NSCLC
Jan 2023 - Jun 2023: Approval in combination with chemotherapy in advanced NSCLC
Checkmark Approved in combination with chemotherapy for 1L treatment of advanced NSCLC
Nov 2022 - Nov 2022: Approved in combination with chemotherapy for 1L treatment of advanced NSCLC
Checkmark Post-hoc exploratory analysis of P3 EMPOWER-Lung 3 trial in advanced NSCLC at ESMO-IO 2022
More
Completed
3
790
Europe, US, RoW
REGN2810, cemiplimab, REGN2810/chemo/ipi, Chemotherapy, Placebo
Regeneron Pharmaceuticals, Sanofi
Non-small Cell Lung Cancer
02/25
02/25
EMPOWER-lung 1, NCT03088540 / 2016-004407-31: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Checkmark Health Canada approved for 1L NSCLC expressing PD-L1 in ≥ 50% of tumour cells
Oct 2021 - Oct 2021: Health Canada approved for 1L NSCLC expressing PD-L1 in ≥ 50% of tumour cells
Checkmark OS and PFS data for advanced or metastatic 1L NSCLC
Jul 2021 - Jul 2021: OS and PFS data for advanced or metastatic 1L NSCLC
Checkmark Approved for 1L advanced NSCLC
More
Active, not recruiting
3
712
Europe, RoW
Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin, cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, Sanofi
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
06/25
06/25
NCT06246916: A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

Recruiting
3
560
US
fianlimab, REGN3767, cemiplimab, REGN2810, LIBTAYO®, relatlimab+nivolumab, Opdualag™
Regeneron Pharmaceuticals
Melanoma
03/27
06/33
NCT06585410: Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Recruiting
3
369
US
Cemiplimab, Libtayo, Standard of care
Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma (CSCC)
05/30
05/30
OliGRAIL, NCT06840782: First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

Not yet recruiting
3
124
Europe
Radical local treatment, SBRT, Interventional radiology, Minimally invasive surgery, SoC-based immunotherapy (+/- chemotherapy)
Gustave Roussy, Cancer Campus, Grand Paris
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
02/25
02/30
NCT06568172: Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Recruiting
3
420
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Image Guided Radiation Therapy, IGRT, Image Guided Radiotherapy, image-guided radiation therapy, Image-Guided Radiotherapy, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Questionnaire Administration, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
National Cancer Institute (NCI)
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Skin Squamous Cell Carcinoma, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Skin Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
08/31
08/31
R3767-ONC-2011, NCT05352672 / 2021-004453-23: Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Calendar Jan 2024 - Dec 2025: Data from trial in combination with fianlimab for 1L advanced melanoma
Calendar Jan 2024 - Dec 2025: Data from trial in combination with Fianlimab for advanced melanoma
Calendar Jan 2024 - Dec 2025: Submission in US in combination with Libtayo for advanced melanoma
Hourglass Jun 2022 - Dec 2022 : Updated data from trial for advanced melanoma
Recruiting
3
1535
Europe, Canada, US, RoW
Fianlimab, REGN3767, Cemiplimab, REGN2810, Libtayo, Pembrolizumab, MK-3475, lambrolizumab, Keytruda, Placebo
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc
Melanoma
06/25
06/31
C-POST, NCT03969004 / 2019-000566-38: Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Calendar Jan 2025 - Dec 2026: Submission for CSCC
Hourglass Jul 2024 - Dec 2024 : Data from trial for adjuvant CSCC
Active, not recruiting
3
415
Europe, Canada, Japan, US, RoW
Cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals, Sanofi
Cutaneous Squamous Cell Carcinoma
11/26
03/28
NCT04157985: Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Recruiting
3
578
US
Continue PD-1/PD-L1 Inhibitors treatment, Keytruda (pembrolizumab), Optiva (nivolumab), Tecentriq (atezolizumab), Yervoy (ipilimumab), LIBTAYO (cemiplimab), Discontinue PD-1/PD-L1-1 inhibitor
Jason J. Luke, MD
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
10/28
10/28
NCT05608291: A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Recruiting
3
1530
Europe, Canada, US, RoW
Fianlimab, REGN3767, Cemiplimab, REGN2810, Libtayo, Pembrolizumab, MK-3475, lambrolizumab, Keytruda, Placebo
Regeneron Pharmaceuticals
Melanoma
05/28
02/30
R3767-ONC-2208, NCT06190951: A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Recruiting
2/3
520
Canada, US, RoW
pembrolizumab, MK-3475, lambrolizumab, Keytruda, Anti-PD1, fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, cemiplimab+fianlimab
Regeneron Pharmaceuticals
Melanoma
09/28
06/33
Lung-MAP Non-Matched Sub-Study, NCT06616584: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Not yet recruiting
2/3
378
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC 1121B, IMC-1121B, IMC1121B, LY 3009806, LY-3009806, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, Regeneron Pharmaceuticals, National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
12/27
12/28
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hourglass Nov 2024 - Dec 2024 : Initial data from trial in combination with Libtayo for advanced NSCLC
Recruiting
2/3
850
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals
Advanced Non-Small Cell Lung Cancer
03/30
02/32
ACTRN12625000197437: Immunotherapy in Perineural Spread of Cutaneous Squamous Cell Carcinoma - IPERCS

Not yet recruiting
2
22
 
Metro South Hospital and Health Services, Regeneron Pharmaceuticals, Inc
Skin Cancer, Cutaneous Squamous Cell Carcinoma
 
 
2019-003007-35: Study of Cemiplimab in Patients with type of skin cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Not yet recruiting
2
76
Europe
cemiplimab, REGN2810, Solution for infusion, Libtayo
Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
Stage II to IV cutaneous squamous cell carcinoma, Type of skin cancer Stage II to IV cutaneous squamous cell carcinoma, Diseases [C] - Cancer [C04]
 
 
2018-003964-30: A study evaluating the clinical benefit of Cemiplimab versus Cemiplimab in combination with RP1 in patients with skin cancer

Not yet recruiting
2
240
Europe, RoW
RP1, LIBTAYO, RP1, Solution for injection, Concentrate for solution for infusion, LIBTAYO
Replimune, Inc., Replimune, Inc, Replimune, Inc.
Advanced Cutaneous Squamous Cell Carcinoma, Advanced skin cancer, Diseases [C] - Cancer [C04]
 
 
2020-003652-32: An experimental study in men and women with head and neck cancer to test the efficacy, safety and tolerability of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activates part of the immune system

Not yet recruiting
2
86
Europe, RoW
Human Papilloma Virus (HPV) type 16 E6/E7 synthetic long peptide (SLP®) vaccine, Cemiplimab, ISA101b, REGN2810, Powder and solvent for suspension for injection, Concentrate for solution for infusion, LIBTAYO
ISA Therapeutics B.V., ISA Therapeutics B.V.
Recurrent/metastatic HPV16- positive Oropharyngeal Cancer (OPC), Head and neck cancer with human papilloma virus type 16 infection, Diseases [C] - Cancer [C04]
 
 
2020-002195-12: A study to investigate novel agent BNT111 and cemiplimab in combination or as single agents in patients with late stage skin cancer that has not responded to other forms of treatment.

Not yet recruiting
2
180
Europe
BNT111, cemiplimab, BNT111, REGN2810, Concentrate for dispersion for injection, Concentrate for solution for infusion, Libtayo
BioNTech SE, BioNTech SE
Anti-PD1-/ PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma, Advanced black skin cancer that is resistant to approved therapies, Diseases [C] - Cancer [C04]
 
 
R2810-ONC-1620, NCT03132636 / 2016-003122-16: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Checkmark Health Canada approved for 2L BCC with a hedgehog pathway inhibitor
Oct 2021 - Oct 2021: Health Canada approved for 2L BCC with a hedgehog pathway inhibitor
Checkmark Approved for advanced or metastatic BCC
Jun 2021 - Jun 2021: Approved for advanced or metastatic BCC
Checkmark Receives CHMP positive opinion for BCC
More
Completed
2
138
Europe, Canada, US
cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, Sanofi
Carcinoma, Basal Cell
05/21
04/23
2021-003266-13: COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2)

Not yet recruiting
2
33
Europe
Keytruda, Libtayo - Cemiplimab, Injection/infusion, Pembrolizumab (KEytruda), Atezolizumab (Tecentriq), Nivolumab (Opdivio), Libtayo (Cemiplimab)
Oslo University Hospital, Oslo university Hospital
Non small cell lung cancer, stage IVPatients are eligible if when they are planned to start immunotherapy according to standard routines and are not in need of radiotherapy, Non small cell lung cancer with extensive disease (metastases) and when immunotherapy is planned to start, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2020-005465-13: Cemiplimab treatment in patients with locally advanced or metastatic blood vessel cancer (angiosarcoma) Onderzoek naar de behandeling met cemiplimab bij patiënten met een lokaal vergevorderde en uitgezaaide kwaadaardige bloedvattumor (angiosarcoom)

Ongoing
2
18
Europe
Cemiplimab, L01XC33, Infusion, LIBTAYO
Radboudumc, Radboudumc, Genzyme Europe B.V.
Patients with locally advanced and metastatic secondary angiosarcomas Patiënten met lokaal vergevorderde en gemetastaseerde secundaire angiosarcomen, Patients with al locally advanced or metastatic blood vessel cancer (secundary angiosarcoma) Patiënten met een lokaal vergevorderde en uitgezaaide kwaadaardige bloedvattumor (angiosarcoom), Diseases [C] - Cancer [C04]
 
 
2020-004052-15: ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with or without platinum-based chemotherapy

Not yet recruiting
2
38
Europe
89Zr-DFO-REGN3767, Libtayo, Solution for injection, Concentrate for concentrate for solution for infusion, Libtayo
University Medical Center Groningen, Regeneron Pharmaceuticals, Inc.
Patients with metastatic solid tumors, where clinical data has shown a rationale for ICI therapy with or without platinum-based chemotherapy, will be included in this study., metastatic solid tumors, Diseases [C] - Cancer [C04]
 
 
R2810-ONC-1901, NCT04154943 / 2019-003007-35: Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Checkmark Presentation of P2 data for neoadjuvant cutaneous squamous cell carcinoma at ESMO 2022
Sep 2022 - Sep 2022: Presentation of P2 data for neoadjuvant cutaneous squamous cell carcinoma at ESMO 2022
Checkmark Data from trial for stage II to IV cutaneous squamous cell carcinoma at ESMO 2022
Sep 2022 - Sep 2022: Data from trial for stage II to IV cutaneous squamous cell carcinoma at ESMO 2022
Active, not recruiting
2
79
Europe, US, RoW
Cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, Sanofi
Cutaneous Squamous Cell Carcinoma
12/21
09/25
2021-000027-12: Immunological variables associated to ICI toxicity in cancer patients

Not yet recruiting
2
441
Europe
atezolizumab, avelumab, cisplatin, axitinib, bevacizumab, cabozantinib, carboplatin, cemiplimab, durvalumab, etoposide, 5-Fluorouracil, ipilimumab, nab-paclitaxel, nivolumab, oxaliplatin, paclitaxel, pembrolizumab, pemetrexed, Concentrate for solution for infusion, Film-coated tablet, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Solution for injection/infusion, Powder for suspension for injection, Concentrate for concentrate for solution for infusion
Institut Jules Bordet, Les amis de Bordet, Fondation Lambeau-Marteaux,, FNRS Télévie
solid tumour, solid tumour, Diseases [C] - Cancer [C04]
 
 
2021-005136-34: A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Not yet recruiting
2
188
Europe
THIO, Libtayo (Cemiplimab), THIO, Concentrate for solution for infusion, Libtayo
MAIA Biotechnology, Inc., MAIA Biotechnology, Inc.
Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NEO-CESQ, NCT04632433 / 2019-001469-34: Neoadjuvant Plus Adjuvant Treatment with Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Active, not recruiting
2
25
Europe
Cemiplimab
Fondazione Melanoma Onlus
Cutaneous Squamous Cell Carcinoma
02/23
02/26
NCT04177810: Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Completed
2
25
US
Cemiplimab, REGN-2810, LIBTAYO, Plerixafor, AMD3100, MOZOBIL
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genzyme, a Sanofi Company, American Association for Cancer Research, National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
03/23
05/23
ICING, NCT04763616: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

Recruiting
2
37
RoW
Isatuximab, Cemiplimab
Won Seog Kim, Sanofi
Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma
04/23
04/26
NCT04646005 / 2020-001239-29: Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Completed
2
113
Europe, US, RoW
Cemiplimab, REGN2810, Libtayo, ISA101b
Regeneron Pharmaceuticals, ISA Pharmaceuticals B.V.
Cervical Cancer
05/23
05/24
NCT05535023: Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Withdrawn
2
26
US
SAR444245, Cemiplimab
M.D. Anderson Cancer Center, Sanofi
Squamous Cell Carcinoma, Oropharynx Cancer, Head and Neck Cancer
07/23
07/23
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
EMPOWER-CSCC-1 , NCT02760498 / 2016-000105-36: Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Checkmark Three-year followup data from a trial for cutaneous squamous cell carcinoma at ASCO 2020
May 2020 - May 2020: Three-year followup data from a trial for cutaneous squamous cell carcinoma at ASCO 2020
Checkmark Post-hoc exploratory analysis from trial for cutaneous squamous cell carcinoma at ASCO 2020
May 2020 - May 2020: Post-hoc exploratory analysis from trial for cutaneous squamous cell carcinoma at ASCO 2020
Checkmark Approved for metastatic/locally advanced CSCC
More
Completed
2
432
Europe, US, RoW
cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals
Advanced Cutaneous Squamous Cell Carcinoma
10/23
10/23
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
NCT04243616: Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

Active, not recruiting
2
36
US
Cemiplimab, Libtayo, Paclitaxel, Taxol, Abraxane, Carboplatin (not mandatory), Paraplatin, Doxorubicin, Lipodox, Lipodox 50, Doxil, Cyclophosphamide, cytophosphane, Cytoxan, Neosar
Medical College of Wisconsin
Invasive Breast Cancer
07/25
08/25
PRIME-CUT, NCT03951831: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Active, not recruiting
2
20
US
REGN2810, Cemiplimab, Degarelix, Firmagon, Leuprolide Acetate, Lupron, Docetaxel, Taxotere
Mark Stein, Regeneron Pharmaceuticals
Prostate Cancer Metastatic
03/24
04/28
NCT04291105: Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
12/24
03/25
RAD-IO, NCT05401786: Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC

Recruiting
2
54
Europe
Ipilimumab, Cemiplimab, SBRT
The Netherlands Cancer Institute, Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
05/24
12/25
NCT05429866: Immunological Variables Associated to ICI Toxicity in Cancer Patients

Recruiting
2
441
Europe
Checkpoint Blockade, Immune, Ipililumab, Nivolumab, Pembrozilumab, atezolizumab, avelumab, durvalumab, Cemiplimab
Jules Bordet Institute
Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Mesothelioma, Malignant, Bladder Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, MSI-H Colorectal Cancer
06/24
12/24
NCT05929664: Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Recruiting
2
35
US
Cemiplimab, 1801342-60-8, Cemiplimab RWLC, Cemiplimab-rwlc, Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Dimer, Libtayo, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized Tomography, CT, CT SCAN, tomography, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI, Biopsy, BIOPSY_TYPE, Bx
Thomas Jefferson University
Locally Advanced Basal Cell Carcinoma
07/27
07/27
THIO-101, NCT05208944 / 2021-005136-34: THIO Sequenced with Cemiplimab in Advanced NSCLC

Hourglass Nov 2024 - Nov 2024 : Safety and efficacy data for NSCLC
Active, not recruiting
2
182
Europe, RoW
6-Thio-2'-Deoxyguanosine, 6-thio-dG, THIO, Cemiplimab, LIBTAYO®
Maia Biotechnology, MAIA Biotechnology, Inc.
Carcinoma, Non-Small-Cell Lung
08/25
10/26
NCT06205836: Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Recruiting
2
22
US
Cemiplimab, REGN2810, LIBTAYO, Fianlimab, REGN3767
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Regeneron Pharmaceuticals
Colorectal Cancer
05/28
05/28
NCT04315701: A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Recruiting
2
34
US
Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810, Resection, Surgical Resection
University of Southern California, National Cancer Institute (NCI)
Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer, Stage III Skin Cancer
06/25
06/26
NCT04238624: Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Active, not recruiting
2
16
US
Dabrafenib, Trametinib
Memorial Sloan Kettering Cancer Center
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors
06/25
06/25
CEMangio, NCT04873375: Cemiplimab for Secondary Angiosarcomas

Completed
2
18
Europe
Cemiplimab, LIBTAYO
Radboud University Medical Center, Genzyme Europe B.V.
Secondary Angiosarcoma, Locally Advanced Sarcoma, Metastasis
10/24
10/24
NCT06161441: A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Recruiting
2
180
US, RoW
Fianlimab, REGN3767, Cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Taxol, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Resectable Non-small Cell Lung Cancer
09/25
04/29
NCT05967884: PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Not yet recruiting
2
20
Canada
Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
Ottawa Hospital Research Institute, Ontario Institute for Cancer Research
Breast Cancer
08/24
08/24
NEO-SURG, NCT06449313: Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Not yet recruiting
2
21
US
Cemiplimab-Rwlc, Libtayo
Georgetown University, Regeneron Pharmaceuticals
Non-small Cell Lung Cancer Stage III
12/27
09/32
NCT06594991: A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Recruiting
2
88
US
Fianlimab, Cemiplimab, Ipilimumab
Memorial Sloan Kettering Cancer Center, Regeneron Pharmaceuticals
Advanced Melanoma
09/27
09/27
VIRO-25, NCT06463665: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Recruiting
2
142
US
Olvimulogene nanivacirepvec, Olvi-Vec, GL-ONC, GLV-1h68, Platinum chemotherapy: carboplatin or cisplatin, Brand of drug is based on institutional procurement, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Genelux Corporation, Newsoara Biopharma Co., Ltd.
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
02/27
07/29
NCT06444880: Phase II Trial of Ubamatamab Alone or in Combination with Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Recruiting
2
40
US
Ubamatamab, Cemiplimab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals
SMARCB1-Deficient Malignancies
07/28
07/28
MINIMA, NCT04988074: Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

Recruiting
2
32
US
Cemiplimab, LIBTAYO
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Regeneron Pharmaceuticals
HPV-Related Squamous Cell Carcinoma
11/25
08/26
NCT06384820: Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Withdrawn
2
140
NA
cemiplimab, REGN2810, Libtayo, fianlimab, REGN3767
Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma
06/26
05/30
NCT06465329: A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
120
Europe, US
Cemiplimab, REGN2810, LIBTAYO, Platinum-based chemotherapy, REGN7075, EGFRxCD28 bispecific immunotherapy
Regeneron Pharmaceuticals
Non-Small Cell Lung Cancer
04/27
05/30
NCT06448026: Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Recruiting
2
17
US
Cemiplimab, Cetuximab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
05/25
05/27
NEOPECS, NCT06418724: Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Not yet recruiting
2
27
NA
Cetuximab, Erbitux, Cemiplimab, Libtayo
Melanoma and Skin Cancer Trials Limited
Locally Advanced Cutaneous Squamous Cell Carcinoma
01/26
12/28
NCT04679480: Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Active, not recruiting
2
20
Europe
Cemiplimab Injection [Libtayo], Sonidegib
Reinhard Dummer, Sanofi, Sun Pharmaceutical Industries Ltd
Basal Cell Carcinoma
12/24
12/24
NCI-2018-01313, NCT03565783: Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Checkmark From P2 trial in head and neck squamous cell cancer at ESMO 2019 [screenshot]
Sep 2019 - Sep 2019: From P2 trial in head and neck squamous cell cancer at ESMO 2019 [screenshot]
Active, not recruiting
2
44
US
Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
12/25
12/25
NCT04862650: Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
46
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
Marcelo Bonomi
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Hypopharyngeal Carcinoma AJCC V8, Stage IV Laryngeal Cancer AJCC V8, Stage IV Lip and Oral Cavity Cancer AJCC V8, Stage IVA Hypopharyngeal Carcinoma AJCC V8, Stage IVA Laryngeal Cancer AJCC V8, Stage IVA Lip and Oral Cavity Cancer AJCC V8, Stage IVB Hypopharyngeal Carcinoma AJCC V8, Stage IVB Laryngeal Cancer AJCC V8, Stage IVB Lip and Oral Cavity Cancer AJCC V8, Stage IVC Hypopharyngeal Carcinoma AJCC V8, Stage IVC Laryngeal Cancer AJCC V8, Stage IVC Lip and Oral Cavity Cancer AJCC V8
12/25
12/25
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
ICARS, NCT06219317: Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

Recruiting
2
136
Europe
Cemiplimab, Placebo
European Organisation for Research and Treatment of Cancer - EORTC
NSCLC Stage IV
01/30
01/30
NCT06699602: A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Recruiting
2
10
US
Cemiplimab, Fianlimab
Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
02/28
02/28
NCT06623656: Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Recruiting
2
112
US
Cemiplimab, Libtayo, REGN2810, Platinum based chemotherapy, Cisplatin, pemetrexed, gemcitabine, carboplatin, paclitaxel, docetaxel, Stereotactic body radiation therapy
Weill Medical College of Cornell University, Regeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
12/26
01/32
NCT06731270: Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Not yet recruiting
2
20
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Diclofenac Potassium, Cambia, Cataflam, CGP 45840B, Zipsor, Electronic Health Record Review, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Emory University, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC V8, Stage IV Lung Cancer AJCC V8
01/26
01/27
NCT06385262: TOP 2301: Neoadjuvant Chemo for NSCLC

Recruiting
2
126
US
Alirocumab, Cemiplimab, Chemotherapy
Duke University, Regeneron Pharmaceuticals
Non Small Cell Lung Cancer
10/27
10/29
NCT06855212: Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Recruiting
2
21
US
Cemiplimab, Cetuximab
H. Lee Moffitt Cancer Center and Research Institute, Eli Lilly and Company, Regeneron Pharmaceuticals
Head and Neck Squamous Cell Carcinoma
03/28
03/28
NCT06769698: A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
120
NA
FDC fianlimab+cemiplimab, REGN3767, REGN2810, Libtayo, Cemiplimab, R2810, Placebo
Regeneron Pharmaceuticals
Head and Neck Squamous Cell Carcinoma (HNSCC)
04/27
11/29
NCT06528769: Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients with Advanced Leiomyosarcoma

Not yet recruiting
2
16
US
all-trans retinoic acid, ATRA, retinoic acid, tretinoin, vitamin A acid, Cemiplimab, libtayo, Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, REGN-2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic resonance imaging, MRI, MRI scan, Magnetic Resonance, Medical Imaging, Nuclear Magnetic Resonance, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection
Gabriel Tinoco
Leiomyosarcoma, Sarcoma
12/27
12/27
TRIPL, NCT06865339: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Not yet recruiting
2
76
US
Cemiplimab, REGN2810 (PD1)_cemiplimab_LIBTAYO, Fianlimab, Radiotherapy, Platinum Doublet Chemotherapy (PDC)
Albert Einstein College of Medicine, Regeneron Pharmaceuticals
NSCLC, Locally Advanced
05/27
05/27
NCT06848088: A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Not yet recruiting
2
98
NA
Fianlimab+cemiplimab, REGN3767, REGN2810, Libtayo®
Regeneron Pharmaceuticals
Melanoma
10/29
10/29
NCT06651593: Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Not yet recruiting
2
40
US
SAR444881, Cemiplimab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals, Sanofi
Solid Tumors
09/28
09/30
NCT03916627: Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Checkmark Results for resectable HCC
Apr 2021 - Apr 2021: Results for resectable HCC
Recruiting
2
73
US
cemiplimab, REGN2810, Libtayo, Platinum Doublet, fianlimab, REGN3767
Regeneron Pharmaceuticals, Sanofi
Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
06/25
03/30
NCT05961709: The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Recruiting
2
50
US
Cemiplimab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals
Colon Cancer
04/26
04/28
NeoSTOP-IT, NCT06571708: Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer

Not yet recruiting
2
36
US
Gemcitabine, Cisplatin, Cemiplimab, REGN 2810, Fianlimab, REGN3767
Columbia University, Regeneron Pharmaceuticals
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
12/28
12/28
Chemo4METPANC, NCT04543071: Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Recruiting
2
10
US
Motixafortide, BL-8040, Cemiplimab, REGN2810, Gemcitabine, Gemzar, Nab paclitaxel, Abraxane
Gulam Manji, Regeneron Pharmaceuticals, BioLine Rx
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
06/28
08/28
LUNGVAC, NCT05344209: Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

Recruiting
2
138
Europe
UV1, Sagramostim, leukine, Anti-PD-1/PD-L1 treatment
Vestre Viken Hospital Trust, University Hospital, Akershus, Oslo University Hospital, Haukeland University Hospital, Helse Stavanger HF, Helse Fonna, Helse Nord-Trøndelag HF, St. Olavs Hospital, Alesund Hospital, Helse Forde, University Hospital of North Norway
Oncology, NSCLC Stage IV, NSCLC, Stage III
07/25
07/27
CERPASS, NCT04050436 / 2018-003964-30: Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Hourglass Jul 2023 - Sep 2023 : Topline data from CERPASS trial in combination with RP1 for advanced CSCC
Checkmark From trial in combination with RP1
Jul 2020 - Dec 2020: From trial in combination with RP1
Active, not recruiting
2
231
Europe, Canada, US, RoW
Cemiplimab, Libtayo, RP1, Genetically modified herpes simplex type 1 virus
Replimune Inc., Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
09/25
09/25
BNT111-01, NCT04526899 / 2020-002195-12: Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Active, not recruiting
2
184
Europe, US, RoW
BNT111, Cemiplimab
BioNTech SE, Regeneron Pharmaceuticals
Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
01/24
07/26
NCT06860815: Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Not yet recruiting
2
11
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Transarterial Radioembolization, Hepatic Radioembolization, TARE, Transarterial Hepatic Radioembolization, Yttrium Y 90 Resin Microspheres, SIR-Spheres, Y-90 Sirsphere
City of Hope Medical Center, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
12/26
12/26
NCT05669989: International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Active, not recruiting
2
70
Europe, Japan, US, RoW
Isatuximab intravenous (IV), SARCLISA®, SAR650984, Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Sanofi
Plasma Cell Myeloma
11/26
11/26
NCT05574101: A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Active, not recruiting
2
34
US
Cemiplimab, Radiotherapy
Memorial Sloan Kettering Cancer Center
Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma of the Skin, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma
10/26
10/26
NCT05553834: PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Recruiting
2
60
US
Alirocumab and Cemiplimab
Duke University, Regeneron Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
01/27
01/29
NCT05557591: A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Recruiting
2
100
Europe, US, RoW
BNT116, Cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, BioNTech SE
Advanced Non-Small Cell Lung Cancer
03/27
06/27
NCT04916002: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Terminated
2
77
US, RoW
vidutolimod, CMP-001, cemiplimab, Libtayo, REGN2810
Regeneron Pharmaceuticals
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
10/24
10/24
NCT05694871: Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Active, not recruiting
2
77
US
Palbociclib, PD-0332991, Cemiplimab, Cemiplimab RWLC, Immunoglobulin G4, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Biospecimen collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8, Unresectable Dedifferentiated Liposarcoma
05/27
05/27
NCT05840770: Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Recruiting
2
34
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Elastography, MRE, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
10/29
10/29
DISCERN, NCT05878288: Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Active, not recruiting
2
11
RoW
Cemiplimab, Libtayo, REGN-2810, REGN2810, cemiplimab-rwlc
Peter MacCallum Cancer Centre, Australia, University of Melbourne, University of Adelaide, Monash University, Regeneron Pharmaceuticals, Sanofi
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms, Non-melanoma Skin Cancer
05/29
05/29
NCT06121180: Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
ZIV-Aflibercept, Zaltrap, Eylea, Cemiplimab, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Genzyme, a Sanofi Company, Regeneron Pharmaceuticals
Metastatic Uveal Melanoma
10/30
10/30
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
JX594-REN026, NCT03294083: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting
1b/2a
89
US, RoW
Pexastimogene Devacirepvec (Pexa-Vec), JX-594, Cemiplimab
SillaJen, Inc., Regeneron Pharmaceuticals
Renal Cell Carcinoma
08/23
11/23
ACTRN12623001077651: A clinical trial to determine the safety and tolerability of GRWD5769 in combination with anticancer treatments in patients with solid malignancies.

Recruiting
1/2
168
 
Grey Wolf Therapeutics Pty Ltd, Grey Wolf Therapeutics Pty Ltd
Advanced solid malignancies
 
 
2019-003298-24: A study to examine REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer

Not yet recruiting
1/2
554
Europe
Libtayo, REGN4018, REGN2810, Concentrate for solution for infusion, Powder for solution for infusion, Powder for solution for injection, Libtayo
Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
Recurrent Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Primary Peritoneal Cancer, Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer, Diseases [C] - Cancer [C04]
 
 
2020-005332-30: A study of SAR444245 combined with cemiplimab for the treatment of participants with various advanced skin cancers Studio di SAR444245 in combinazione con cemiplimab per il trattamento di pazienti con vari tumori cutanei in stadio avanzato

Not yet recruiting
1/2
100
Europe
NA, cemiplimab, [SAR444245], [REGN2810], Concentrate for solution for infusion
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi Aventis Recherche & Développement
Advanced unresectable or metastatic skin cancers Tumori cutanei non resecabili o metastatici in stadio avanzato, Skin Cancer Tumore cutaneo, Diseases [C] - Cancer [C04]
 
 
2022-002234-14: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies

Ongoing
1/2
140
Europe
OR2805, Libtayo, OR2805, Infusion, Libtayo / Cemiplimab
OncoResponse, Inc., OncoResponse, Inc.
Solid tumor cancer, Cancer/ solid tumors, Diseases [C] - Cancer [C04]
 
 
CONTRAC, NCT04339062: Cemiplimab in AlloSCT/SOT Recipients With CSCC

Active, not recruiting
1/2
12
US
Cemiplimab, Libtayo, Everolimus, Afinitor, Zortress, Sirolimus, Rapamune, Prednisone, Deltasone, Prednicot, predniSONE Intensol, Rayos, Sterapred, Sterapred DS
Dana-Farber Cancer Institute, Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
06/23
01/26
NCT03194867 / 2017-001431-39: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Hourglass Jan 2021 - Dec 2021 : From trial in combination with isatuximab for r/r multiple myeloma
Hourglass Jan 2020 - Dec 2020 : OS secondary analysis data from trial in combination with isatuximab for r/r multiple myeloma
Completed
1/2
109
Europe, Canada, US, RoW
Isatuximab SAR650984, Sarclisa, Cemiplimab REGN2810
Sanofi
Plasma Cell Myeloma
04/23
04/23
NCT03690869 / 2023-000604-19: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Calendar Jan 2025 - Dec 2025: From trial n pediatrics with solid tumors
Terminated
1/2
57
US
cemiplimab (monotherapy), REGN2810, Libtayo, cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Regeneron Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
05/23
05/23
NCT04913220: A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Terminated
1/2
46
Europe, US, RoW
THOR-707, Cemiplimab, Libtayo® or generic
Sanofi
Malignant Melanoma, Squamous Cell Carcinoma of Skin
08/23
02/25
 

Download Options